Provider: Edison Investment Research
Tigenix NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Grifols SA’s Subsidiary Acquires 21.30% Stake In TiGenix NV
Grifols SA announced that it has acquired a 21.30% stake in TiGenix NV for the price of EUR 12 million. The transaction was carried out by Grifols SA’s wholly owned subsidiary, Gri-Cel SA.
Latest Key Developments in Biotechnology
- Flex Pharma Inc announces pricing of initial public offering
- PAREXEL International Corp lowers FY 2015 revenue guidance; raises FY 2015 EPS guidance; gives Q3 2015 EPS guidance; revenue guidance below analysts' estimates
- Radius Health Inc announces closing of public offering of common stock and full exercise of underwriters' option to purchase additional shares
- Vaccinogen Inc closes second tranche of $80 mln financing at $5.50 per unit
- Share this
- Digg this